Adenine nucleotide translocator 1, 2, and 3 (ANT1/2/3)

ADP/ATP translocases, also known as Adenine Nucleotide Translocators (ANTs), are essential mitochondrial proteins that facilitate the exchange of ADP and ATP across the inner mitochondrial membrane (UniProt P12235, P05141, P12236). This process is critical for maintaining cellular energy homeostasis, as it allows ATP generated by oxidative phosphorylation to reach the cytosol while returning ADP to the mitochondrial matrix for re-phosphorylation (PubMed: 26510443). In humans, there are three primary isoforms: ANT1 (SLC25A4), ANT2 (SLC25A5), and ANT3 (SLC25A6), which exhibit tissue-specific expression patterns and distinct roles in cellular metabolism and apoptosis (NCBI Gene: 291, 292, 293). Beyond their transport function, ANTs are key components of the mitochondrial permeability transition pore (mPTP), making them significant regulators of programmed cell death (PubMed: 15155841). Dysregulation or mutations in these proteins are linked to various pathologies, including mitochondrial myopathies, cardiomyopathies, and cancer, where ANT2 is frequently upregulated to support rapid proliferation (PubMed: 17331888). Pharmacological targeting of ANTs, using inhibitors like atractyloside or experimental anti-cancer agents like MT-21, aims to modulate mitochondrial function or induce apoptosis in malignant cells (PubChem CID 441311).

Other names

ADP/ATP translocaseSolute carrier family 25 member 4/5/6Adenine nucleotide carrierADP,ATP carrier proteinSLC25A4SLC25A5SLC25A6

Inhibition of the mitochondrial ADP/ATP exchange process or modulation of the mitochondrial permeability transition pore (mPTP) to induce or inhibit apoptosis (PubMed: 15155841).